Sustained Benefit in Patients With Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 31/2-Year Follow-Up Data of IMBRUVICA(R) (ibrutinib)
December 09, 2017
December 09, 2017
ATLANTA, Georgia, Dec. 9 -- Johnson and Johnson issued the following news release:
Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with IMBRUVICA(R) (ibrutinib). The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability. These data ( . . .
Today, Janssen Research & Development, LLC (Janssen) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with IMBRUVICA(R) (ibrutinib). The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability. These data ( . . .